Spectris (SXS) Q3 2024 TU earnings summary

Executive summary

• Order intake and sales declined 10% and 6% year-over-year, with Q3 2024 showing market stabilization but slower-than-expected recovery, especially in China, pharma, and academia.

• Strategic acquisitions (Micromeritics, SciAps, Piezocryst) and ERP implementation are progressing well, supporting future growth.

• Accelerated cost reduction, restructuring, and a profit improvement program targeting £50 million in benefits are underway, with at least £30 million expected in 2025.

Financial highlights

• Group reported sales fell 13% to £302.7m in Q3 2024 from £349.1m in Q3 2023; like-for-like sales down 10%.

• Adjusted operating profit for the full year is expected to be around £200 million, including acquisitions.

• Net debt stood at £393 million at period end; leverage expected at the upper end of the 1–2x net debt/EBITDA range if Piezocryst acquisition completes.

Outlook and guidance

• Market trends from H1 are expected to persist, with continued weakness in China, pharma, and academia into early 2025.

• Order book at end of Q3 was over £530 million, providing about 4.5 months of order cover.

• Guidance revised down, reflecting a balanced risk-adjusted approach; some weakness expected to extend into Q1 2025.